Oral Anti-Diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Reportlinker.com has recently published a report titled "Analysis of the Size and Share of the Market for Oral Anti-Diabetic Drugs - Trends and Forecasts for Growth from 2023 to 2028". This report provides in-depth insights and analysis on the market for oral anti-diabetic drugs and its expected growth trends in the coming years. If you are interested in understanding the current market scenario and future prospects of oral anti-diabetic drugs, you can access the report through the following link: https://www.reportlinker.com/p06483830/?utm_source=GNW.

Experts predict that the market will surpass a staggering USD 52 billion by the year 2027.

The oral anti-diabetic drugs market has been significantly impacted by the COVID-19 pandemic. The number of individuals with diabetes who are being hospitalized with COVID-19 infections has highlighted the importance of improving glycemic control to enhance outcomes and reduce hospital stays for patients with SARS-CoV-2. Individuals with diabetes have a compromised immune system, making them more susceptible to the complications of COVID-19. Additionally, diabetes and uncontrolled hyperglycemia are risk factors for negative outcomes in COVID-19 patients, including an elevated risk of severe illness or death. As a result, the global growth of the oral anti-diabetic drugs market has been accelerated by the COVID-19 outbreak.

The adult population with diabetes is estimated to be around 537 million in 2021, as reported by the International Diabetes Federation (IDF). This number is expected to rise to 643 million by 2030. The rate at which people are being diagnosed with both Type 1 and Type 2 diabetes is increasing due to factors such as obesity, unhealthy eating habits, and lack of physical activity. The growing number of individuals with diabetes and the associated healthcare costs worldwide point to an increasing reliance on anti-diabetic medications. Advances in technology and innovations have led to various changes in the drugs and formulations being developed.

As a result of the factors mentioned above, it is expected that the market under investigation will experience an increase in its growth during the period of analysis.

Trends in the market for medications to treat diabetes orally.

The Biguanide category has captured the largest portion of the market in the present year for oral medications aimed at treating diabetes.

The Biguanide Segment has the largest portion, accounting for approximately 45% of the current market share in Oral Anti-Diabetic Drugs.

Metformin is a type of medicine that is used to treat type 2 diabetes. It is also sometimes given to people with insulin resistance, even though this is not its main purpose. Metformin has been very successful in treating patients with type 2 diabetes and is widely available around the world. It is considered to have a good balance of benefits and risks and is often recommended as the first choice of drug by medical guidelines. Many people have had positive experiences using metformin over the long term, and there is strong evidence that it is effective and safe. It is also affordable and easy to find, which has helped it become very popular. Because of these factors, metformin is included on the World Health Organization's list of essential medicines, which are the medicines that the population needs most.

Biguanides are a group of drugs utilized in the management of type 2 diabetes. Their mechanism of action involves suppressing the generation of glucose during the process of digestion. Currently, metformin stands as the sole biguanide accessible in the majority of countries for diabetes treatment. Glucophage (metformin) and Glucophage XR (metformin extended release) are widely recognized trade names for these medications. Additional options include Fortamet, Glumetza, and Riomet. Metformin is also available in conjunction with various other diabetes medications, including sulfonylureas.

Zydus Lifesciences made public in July 2022 that it was given the green light to sell Empagliflozin and Metformin Hydrochloride tablets in various potencies. These tablets, when taken alongside a suitable diet and exercise routine, help enhance glycemic control in adults suffering from type 2 diabetes mellitus. Moreover, they are effective in reducing the likelihood of cardiovascular-related deaths in patients diagnosed with type 2 diabetes mellitus and preexisting cardiovascular conditions.

Due to the aforementioned reasons and the rising frequency, it is highly probable that the market will continue to expand.

The Oral Anti-Diabetic Drugs Market is anticipated to experience substantial growth in the Asia-Pacific Region, with the highest compound annual growth rate (CAGR) expected during the forecast period.

The Asia-Pacific area is anticipated to experience a Compound Annual Growth Rate (CAGR) of over 4% throughout the projected timeframe.

As per the International Diabetes Federation, there were around 90 million grown-ups combating diabetes in the South-East Asia Region of IDF, while it was about 206 million adults in the Western Pacific Region in the year 2021. By 2030, it is anticipated that these numbers will spike to 113 million and 238 million respectively. The popularity of oral medications for diabetes treatment is surging due to the emergence of advanced oral drugs like DPP-4 and SGLT-2, which effectively lower the risk of cardiovascular complications in patients with diabetes.

China and Japan are seen as promising emerging markets in the Asia-Pacific area because of the expanding number of people with diabetes. Japan, in particular, is an advanced market that faces certain difficulties such as sluggish economic advancement, an aging populace, and heightened rivalry. There has been a noticeable rise in the number of manufacturers producing generic drugs in the country. Additionally, the prominent international companies operating in this market are facing fierce competition from local players.

Diabetes, a condition that reduces lifespan, can lead to various complications such as blindness and the need for hospitalization due to amputations, kidney failure, heart attacks, strokes, and heart failure. In patients with type 2 diabetes (T2D), the preferred initial treatment is metformin alone. However, alternative options must be explored if metformin is not suitable or if treatment goals are not met after three months of using the highest tolerated dose. The range of medications available for diabetes management has expanded and now includes dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists. These drugs are typically used in addition to metformin therapy.

It is anticipated that the market will experience growth throughout the projected timeframe owing to the aforementioned factors.

Overview of the Oral Anti-Diabetic Drugs Sector

The market for oral medication for diabetes is somewhat divided, with prominent companies such as Eli Lilly, AstraZeneca, Sanofi, Janssen Pharmaceuticals, and others having a worldwide presence. On the other hand, the rest of the manufacturers are limited to specific local or regional markets.

The Excel spreadsheet for market estimation (ME) is available with 3 months of analyst assistance. To access the complete report, visit this link: https://www.reportlinker.com/p06483830/?utm_source=GNW

What is Reportlinker? Reportlinker is a renowned market research service that has been recognized for its excellence. Reportlinker gathers and arranges up-to-date information on various industries, ensuring that you have access to all the market research you require conveniently, all in a single location.